Top 10 MG news stories of 2025
A double dose of Vyvgart news, research advances headline this year's recap
Written by |
In 2025, Myasthenia Gravis News delivered readers timely reporting on research, treatments, and clinical trials for myasthenia gravis (MG).
We have compiled the 10 most-read stories for a recap of the year, each accompanied by a brief summary. As we enter 2026, we look forward to continuing our support of the MG community.
No. 10 – Very-late-onset gMG may be more aggressive initially
A study in Greece found that older adults whose generalized MG (gMG) begins to manifest at or after age 65 tend to experience a more aggressive disease course at the start, requiring additional breathing support early on. In gMG, a severe form of MG, symptoms affect multiple parts of the body. People with very-late-onset gMG tended to do better in the two years after diagnosis, despite using lower doses of corticosteroids, a type of anti-inflammatory medication, than people with earlier-onset gMG.
No. 9 – Treatment-resistant autoantibodies may influence gMG severity
Researchers in the U.S. have found that certain subsets of gMG patients carry self-reactive antibodies, or autoantibodies, that drive disease and can persist despite treatment. These treatment-resistant autoantibodies can vary over time in their binding strength to their targets, which may influence the severity of symptoms and their progression. The findings suggest that profiling such autoantibodies could be useful in future clinical trials to better understand their potential links with response to treatment.
No. 8 – Cancer drug effective in 2 women with difficult-to-treat gMG
Blinatumomab, a blood cancer medication marketed under the brand name Blincyto, led to rapid and sustained reductions in disease symptoms and their impact in two women with severe, treatment-resistant gMG in Germany. The therapy works by prompting immune T-cells to kill B-cells, the immune cells responsible for producing antibodies, including the autoantibodies that cause MG. While this evidence comes from only two cases, it suggests that blinatumomab may offer a new treatment approach for difficult-to-treat autoimmune diseases such as MG.
No. 7 – Arthritis medication tofacitinib eases MG in rat model
Tofacitinib — an oral medication approved for several forms of inflammatory arthritis and a type of inflammatory bowel disease — lessened muscle weakness and weight loss in a rat model of MG. The therapy also promoted a shift toward an anti-inflammatory profile in lab-grown immune cells from MG patients. Tofacitinib, marketed under the brand name Xeljanz, works by blocking the activity of JAK enzymes, which play a key role in inflammation and the immune response. While these preclinical findings point to tofacitinib as a potential treatment for MG, further studies are needed to test it in people with MG.
No. 6 – Vyvgart outperforms standard treatment in real-world study
Real-world data showed that Argenx’s Vyvgart (efgartigimod alfa-fcab) eases symptoms of MG more rapidly and to a greater extent than standard corticosteroids and immunosuppressants. Adults with MG who were treated with Vyvgart were more likely to achieve minimal symptoms and saw substantial improvements in muscles involved in breathing, speech, and swallowing.
No. 5 – Combined procedure delivers better outcomes in myasthenic crises
Researchers in China found that applying a combined therapeutic procedure as a treatment for myasthenic crises — a serious complication of MG that typically requires hospitalization and breathing support — led to better outcomes compared with standard approaches. The combined approach, called lymphoplasmapheresis, involves two procedures that remove antibodies and immune cells from the patient’s blood. It was found to be superior to the removal of antibodies alone, a procedure known as plasmapheresis, with fewer treatment sessions.
No. 4 – Enrollment opens in early trial of NKX019 cell treatment
Nkarta announced in May that enrollment had begun in an investigator-initiated Phase 1 clinical trial testing NKX019, its experimental cell-based treatment for gMG. This study, which will assess the safety and pharmacological properties of the therapy, represents an early step in testing whether engineered immune cells in NKX019 can provide durable improvements in MG by targeting disease-driving pathways.
No. 3 – Vyvgart effective in triple-seronegative gMG
Three women with triple-seronegative gMG — a form lacking the most common disease-causing autoantibodies — responded well to treatment with Vyvgart, according to a case series from China. The therapy is approved for adults with gMG who are positive for autoantibodies targeting the acetylcholine receptor (AChR) — the most common type of MG-causing antibody. One woman’s symptoms resolved within one month, and all women showed clinical benefits, suggesting Vyvgart may help even in people with difficult-to-treat triple-seronegative disease.
No. 2 – Living with MG: Patients share daily tips for better quality of life
A patient-centered webinar presented by Myasthenia Gravis News highlighted strategies for managing daily life with MG. The panel of experts and patients emphasized the importance of managing stress, prioritizing rest, adapting routines to conserve energy, tracking symptoms, and building strong partnerships with healthcare providers. The discussion also offered guidance on navigating information sources, including digital tools.
No. 1 – FDA approves Imaavy for treating gMG
The U.S. Food and Drug Administration approved Imaavy (nipocalimab-aahu) in May for treating gMG in adults and adolescents, ages 12 and older, with autoantibodies against AChR or muscle-specific kinase proteins (another common target of MG-driving antibodies). Imaavy belongs to a class of therapies called FcRn blockers that accelerate the breakdown of antibodies, and it is the only treatment in its class approved for both pediatric and adult patients with either type of MG-driving autoantibody. In clinical trials, the therapy was shown to significantly reduce the severity of MG in this patient population.
We hope our stories in 2025 have been helpful, and we wish everyone a fulfilling new year.
Leave a comment
Fill in the required fields to post. Your email address will not be published.